Adherium (ASX:ADR), a digital health company focussed on improving patient medication adherence and health outcomes, has released SmartTurbo Model 4, the next generation of the company’s adherence monitoring technology for AstraZeneca’s Turbuhaler medication.
According to the company, the SmartTurbo Model 4 includes usability improvements to make the installation and removal of the Turbuhaler easier for older patients with COPD.
"The device also features a series of new larger buttons that help patients easily access new optional device features, including audio visual-reminders, battery monitoring, and Bluetooth low-energy (BLE) pairing," said the company in a statement.
New sensors have been added to generate more data for monitoring and providing feedback on correct use of the inhaler for priming, inhalation, and closing of the medication at each use.
Arik Anderson, Adherium CEO, said, “We believe that SmartTurbo Model 4 will address a key unmet need for patients with asthma or chronic obstructive pulmonary disease by monitoring and improving adherence to their medications. We are now demonstrating the ability to design, obtain regulatory approvals, transfer to production, and release to market, on an annual cycle – improving the device with each successive generation.”
The SmartTurbo Model 4 is the latest output from the long-term strategic partnership between AstraZeneca and Adherium.